keyword
MENU ▼
Read by QxMD icon Read
search

atypical antipsychotic

keyword
https://www.readbyqxmd.com/read/28734929/aripiprazole-prevents-renal-ischemia-reperfusion-injury-in-rats-probably-through-nitric-oxide-involvement
#1
Hanieh Gholampour, Leila Moezi, Hamed Shafaroodi
Renal ischemia/reperfusion (I/R) injury is strongly related to morbidity and mortality. Oxidative stress, inflammation, and apoptosis play key roles in renal dysfunction following renal I/R. Aripiprazole is an atypical antipsychotic which used for the treatment of schizophrenia and bipolar disorder. Recent studies have reported aripiprazole as displaying certain anti-inflammatory effects. Regarding the underlying mechanisms of renal ischemia-reperfusion, therefore, nephroprotective effects might be predicted to be seen with aripiprazole...
July 19, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28716726/early-life-risperidone-enhances-locomotor-responses-to-amphetamine-during-adulthood
#2
Bobbie Lee Stubbeman, Clifford J Brown, Justin R Yates, Mark E Bardgett
Antipsychotic drug prescriptions for pediatric populations have increased over the past 20 years, particularly the use of atypical antipsychotic drugs such as risperidone. Most antipsychotic drugs target forebrain dopamine systems, and early-life antipsychotic drug exposure could conceivably reset forebrain neurotransmitter function in a permanent manner that persists into adulthood. This study determined whether chronic risperidone administration during development modified locomotor responses to the dopamine/norepinephrine agonist, D-amphetamine, in adult rats...
July 14, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28715903/parkinson-s-disease-and-parkinson-s-disease-psychosis-a-perspective-on-the-challenges-treatments-and-economic-burden
#3
Doral Fredericks, James C Norton, Carolyn Atchison, Robert Schoenhaus, Michael W Pill
Parkinson's disease (PD) is a progressive neurodegenerative disease associated with a decrease in the neurotransmitter dopamine and characterized by the cardinal motor hallmarks of resting tremor, rigidity, bradykinesia/akinesia, and postural instability. Lesser-known features of PD revolve around nonmotor concerns including psychosis, dementia, sleep disturbances, autonomic dysfunction, and sensory abnormalities. Parkinson's disease psychosis (PDP) contributes significantly to morbidity, mortality, nursing home placement, and quality of life (QOL)...
April 2017: American Journal of Managed Care
https://www.readbyqxmd.com/read/28712616/aripiprazole-lauroxil-compared-with-paliperidone-palmitate-in-patients-with-schizophrenia-an-indirect-treatment-comparison
#4
REVIEW
Chris Cameron, Jacqueline Zummo, Dharmik N Desai, Christine Drake, Brian Hutton, Ahmed Kotb, Peter J Weiden
BACKGROUND: Aripiprazole lauroxil (AL) is a long-acting injectable atypical antipsychotic recently approved for treatment of schizophrenia on the basis of a large-scale trial of two doses of AL versus placebo. There are no direct-comparison studies with paliperidone palmitate (PP; long-acting antipsychotic used most often in acute settings) for the acute psychotic episode. OBJECTIVES: To indirectly compare efficacy and safety of the pivotal AL study with all PP studies meeting indirect comparison criteria...
July 2017: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/28709776/effects-of-four-atypical-antipsychotics-on-autonomic-nervous-system-activity-in-schizophrenia
#5
Saki Hattori, Ikuko Kishida, Akira Suda, Masatoshi Miyauchi, Yohko Shiraishi, Mami Fujibayashi, Natsuki Tsujita, Chie Ishii, Norio Ishii, Toshio Moritani, Masataka Taguri, Yoshio Hirayasu
Antipsychotic drugs are associated with autonomic nervous system (ANS) dysfunction in patients with schizophrenia, but the effects of individual atypical antipsychotic drugs are not clear. This study investigated how four atypical antipsychotic drugs-risperidone, olanzapine, aripiprazole, and quetiapine-differ in their effects on ANS activity. A total of 241 Japanese patients with schizophrenia participated in this study. All of the participants received an atypical antipsychotic as monotherapy: 90 participants received risperidone, 68 olanzapine, 52 aripiprazole, and 31 quetiapine...
July 12, 2017: Schizophrenia Research
https://www.readbyqxmd.com/read/28707161/a-weight-independent-association-between-atypical-antipsychotic-medications-and-obstructive-sleep-apnea
#6
Habibolah Khazaie, Amir Sharafkhaneh, Sepideh Khazaie, Mohammad Rasoul Ghadami
BACKGROUND: With increasing use of atypical antipsychotic (AAP) agents, the concern has been raised about the association between AAP agents and medical complications. Obstructive sleep apnea (OSA) is a common breathing disorder that adversely affects health and quality of life. Because the major risk factors for OSA are weight gain and obesity by altering the upper airway anatomy, an association between AAP and development of OSA is predictable. However, we hypothesized that AAP may promote OSA not only by weight gain but also because of its potential effects on upper airway muscle function...
July 13, 2017: Sleep & Breathing, Schlaf & Atmung
https://www.readbyqxmd.com/read/28705535/clozapine-blockade-of-mk-801-induced-learning-memory-impairment-in-the-mepm-role-of-5-ht1a-receptors-and-hippocampal-bdnf-levels
#7
Ximena López Hill, Analía Richeri, María Cecilia Scorza
Cognitive impairment associated with schizophrenia (CIAS) is highly prevalent and affects the overall functioning of patients. Clozapine (Clz), an atypical antipsychotic drug, significantly improves CIAS although the underlying mechanisms remain under study. The role of the 5-HT1A receptor (5-HT1A-R) in the ability of Clz to prevent the learning/memory impairment induced by MK-801 was investigated using the modified elevated plus-maze (mEPM) considering the Transfer latency (TL) as an index of spatial memory...
July 10, 2017: Physiology & Behavior
https://www.readbyqxmd.com/read/28705298/methamphetamine-related-disorders
#8
Euphrosyne Gouzoulis-Mayfrank, Roland Härtel-Petri, Willem Hamdorf, Ursula Havemann-Reinecke, Stephan Mühlig, Norbert Wodarz
BACKGROUND: Methamphetamine is considered more dangerous than other stimulants because of its acute complications, long-term neurotoxicity, and potential for drug dependence. Until now, there have been no evidence-based guidelines for the treatment of methamphetamine-related disorders, either in Germany or abroad. METHODS: A systematic literature search was performed on the treatment of methamphetamine-related disorders. Based on this literature review, a multidisciplinary expert panel developed recommendations using the nominal group technique...
June 30, 2017: Deutsches Ärzteblatt International
https://www.readbyqxmd.com/read/28700116/an-integrative-literature-review-exploring-the-clinical-management-of-delirium-in-patients-with-advanced-cancer
#9
REVIEW
Hayley Lawley, Alistair Hewison
AIM: The aim of this paper is to present the findings of an integrative literature review of the evidence for the clinical management of delirium in patients with advanced cancer. BACKGROUND: Patients with advanced cancer frequently experience delirium which can be distressing for both patients and their families. Current guidelines recommend that underlying causes of the delirium be addressed and a course of antipsychotics considered. However the research into the effectiveness of treatments for delirium in people with advanced cancer is limited...
July 12, 2017: Journal of Clinical Nursing
https://www.readbyqxmd.com/read/28697253/effect-of-antidepressant-switching-vs-augmentation-on-remission-among-patients-with-major-depressive-disorder-unresponsive-to-antidepressant-treatment-the-vast-d-randomized-clinical-trial
#10
RANDOMIZED CONTROLLED TRIAL
Somaia Mohamed, Gary R Johnson, Peijun Chen, Paul B Hicks, Lori L Davis, Jean Yoon, Theresa C Gleason, Julia E Vertrees, Kimberly Weingart, Ilanit Tal, Alexandra Scrymgeour, David D Lawrence, Beata Planeta, Michael E Thase, Grant D Huang, Sidney Zisook, Sanjai D Rao, Patricia D Pilkinton, James A Wilcox, Ali Iranmanesh, Mamta Sapra, George Jurjus, James P Michalets, Muhammed Aslam, Thomas Beresford, Keith D Anderson, Ronald Fernando, Sriram Ramaswamy, John Kasckow, Joseph Westermeyer, Gihyun Yoon, D Cyril D'Souza, Gunnar Larson, William G Anderson, Mary Klatt, Ayman Fareed, Shabnam I Thompson, Carlos J Carrera, Solomon S Williams, Timothy M Juergens, Lawrence J Albers, Clifford S Nasdahl, Gerardo Villarreal, Julia L Winston, Cristobal A Nogues, K Ryan Connolly, Andre Tapp, Kari A Jones, Gauri Khatkhate, Sheetal Marri, Trisha Suppes, Joseph LaMotte, Robin Hurley, Aimee R Mayeda, Alexander B Niculescu, Bernard A Fischer, David J Loreck, Nicholas Rosenlicht, Steven Lieske, Mitchell S Finkel, John T Little
Importance: Less than one-third of patients with major depressive disorder (MDD) achieve remission with their first antidepressant. Objective: To determine the relative effectiveness and safety of 3 common alternate treatments for MDD. Design, Setting, and Participants: From December 2012 to May 2015, 1522 patients at 35 US Veterans Health Administration medical centers who were diagnosed with nonpsychotic MDD, unresponsive to at least 1 antidepressant course meeting minimal standards for treatment dose and duration, participated in the study...
July 11, 2017: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/28696411/combined-study-of-genetic-and-epigenetic-biomarker-risperidone-treatment-efficacy-in-chinese-han-schizophrenia-patients
#11
Y Shi, M Li, C Song, Q Xu, R Huo, L Shen, Q Xing, D Cui, W Li, J Zhao, L He, S Qin
Nowadays, risperidone is an atypical antipsychotic drug that has been increasingly used for treatment and maintenance therapy in schizophrenia. However, partially affected by genetic or environmental factors, there is significant difference in treatment outcomes among patients. In this study, we aimed to interpret the difference between good and poor responders treated with risperidone in both genetic and epigenetic levels in 288 mainland Chinese patients. We recruited a Henan cohort including 98 patients as initial discovery group and then confirmed our results in Shanghai cohort...
July 11, 2017: Translational Psychiatry
https://www.readbyqxmd.com/read/28691250/obesity-in-patients-with-major-depression-is-related-to-bipolarity-and-mixed-features-evidence-from-the-bridge-ii-mix-study
#12
Eleonora Petri, Olivia Bacci, Margherita Barbuti, Isabella Pacchiarotti, Jean-Michel Azorin, Jules Angst, Charles L Bowden, Sergey Mosolov, Eduard Vieta, Allan H Young, Giulio Perugi
OBJECTIVES: The Bipolar Disorders: Improving Diagnosis, Guidance and Education (BRIDGE)-II-Mix study aimed to estimate the frequency of mixed states in patients with a major depressive episode (MDE) according to different definitions. The present post-hoc analysis evaluated the association between obesity and the presence of mixed features and bipolarity. METHODS: A total of 2811 MDE subjects were enrolled in a multicenter cross-sectional study. In 2744 patients, the body mass index (BMI) was evaluated...
July 10, 2017: Bipolar Disorders
https://www.readbyqxmd.com/read/28689816/a-novel-role-for-dopamine-signaling-in-the-pathogenesis-of-bone-loss-from-the-atypical-antipsychotic-drug-risperidone-in-female-mice
#13
Katherine J Motyl, Megan Beauchemin, Deborah Barlow, Phuong T Le, Kenichi Nagano, Annika Treyball, Anisha Contractor, Roland Baron, Clifford J Rosen, Karen L Houseknecht
Atypical antipsychotic (AA) drugs, including risperidone (RIS), are used to treat schizophrenia, bipolar disorder, and autism, and are prescribed off-label for other mental health issues. AA drugs are associated with severe metabolic side effects of obesity and type 2 diabetes. Cross-sectional and longitudinal data also show that risperidone causes bone loss and increases fracture risk in both men and women. There are several potential mechanisms of bone loss from RIS. One is hypogonadism due to hyperprolactinemia from dopamine receptor antagonism...
July 6, 2017: Bone
https://www.readbyqxmd.com/read/28686559/-attenuated-psychosis-syndrome-a-new-diagnostic-category-for-further-study-in-dsm-5
#14
G Samiotakis, C Kollias, H Lazaratou, D Anagnostopoulos, V Kontaxakis
In recent years an increasing number of studies focus on the issue of early diagnosis and intervention. At the same time, a large number of special service units for early psychosis have been established around the world especially in Australia, USA, UK, Germany etc. Recently, similar units operate in Greece also. The Diagnostic Manual of Mental Disorders of the American Psychiatric Association in its latest edition in 2013 (DSM-5), introduced the category "Attenuated Psychosis Syndrome" (APS) for people with early psychotic experiences in the section: "Conditions for further study '...
April 2017: Psychiatrikē, Psychiatriki
https://www.readbyqxmd.com/read/28685626/lurasidone-for-the-treatment-of-irritability-and-anger-in-autism-spectrum-disorders
#15
Lynn McClellan, Kelli C Dominick, Ernest V Pedapati, Logan K Wink, Craig A Erickson
Autism Spectrum Disorder (ASD) is a heterogeneous neurodevelopmental disorder characterized by deficits in social interaction and communication as well as restricted patterns of behaviors and interests. Irritability marked by tantrums, self-injury and aggression occurs frequently in youth with ASD, causing significant parent and caregiver distress. Atypical antipsychotics have been the most studied drug class targeting irritability in ASD. Risperidone and aripiprazole are Food and Drug Administration (FDA)-approved atypical antipsychotics for treatment of irritability in youth with ASD...
July 24, 2017: Expert Opinion on Investigational Drugs
https://www.readbyqxmd.com/read/28684359/significance-of-the-nicotinic-alpha7-receptor-in-cognition-and-antipsychotic-like-behavior-in-the-rat
#16
Marie-Louise G Wadenberg, Dina Manetti, Maria Novella Romanelli, Hugo R Arias
Schizophrenic (SCH) patients show cognitive impairment in attentional performance. Positive allosteric modulators (PAMs) of α7 nicotinic acetylcholine receptors (nAChRs) such as the Alzheimer's drug galantamine (GAL) and PAM-2 are documented to have pro-cognitive properties. However, it is not well established if these properties would be lost, or may hamper antipsychotic efficacy, when given as an adjunct to an antipsychotic which is needed for managing psychotic symptoms. Using adult male Wistar rats, we here investigated the effects of: a) GAL, alone or co-administered with the antipsychotic risperidone (RISP), on acute phencyclidine (PCP)-induced deficits in the attentional set-shifting (ASST) test; b) PAM-2, alone and co-administered with RISP, in the conditioned avoidance response (CAR) test for antipsychotic activity...
July 3, 2017: Behavioural Brain Research
https://www.readbyqxmd.com/read/28673279/pharmacogenetic-evaluation-to-assess-breakthrough-psychosis-with-aripiprazole-long-acting-injection-a-case-report
#17
Seenae Eum, Mark E Schneiderhan, Jacob T Brown, Adam M Lee, Jeffrey R Bishop
BACKGROUND: Given the complex nature of symptom presentation and medication regimens, psychiatric clinics may benefit from additional tools to personalize treatments. Utilizing pharmacogenetic information may be helpful in assessing unique responses to therapy. We report herein a case of wearing-off phenomena during treatment with aripiprazole long-acting injectable (LAI) and a proof of concept strategy of how pharmacogenetic information may be used to assess possible genetic factors and also hypothesize potential mechanisms for further study...
July 3, 2017: BMC Psychiatry
https://www.readbyqxmd.com/read/28671376/insomnia-pharmacologic-therapy
#18
Eric Matheson, Barry L Hainer
Insomnia accounts for more than 5.5 million visits to family physicians each year. Although behavioral interventions are the mainstay of treatment, pharmacologic therapy may be necessary for some patients. Understanding the risks and benefits of insomnia medications is critical. Controlled-release melatonin and doxepin are recommended as first-line agents in older adults; the so-called z-drugs (zolpidem, eszopiclone, and zaleplon) should be reserved for use if the first-line agents are ineffective. For the general population with difficulty falling asleep, controlled-release melatonin and the z-drugs can be considered...
July 1, 2017: American Family Physician
https://www.readbyqxmd.com/read/28669135/changes-over-the-last-15-years-in-the-psychopharmacological-management-of-persons-with-borderline-personality-disorder
#19
A Martín-Blanco, A Ancochea, J Soler, M Elices, C Carmona, J C Pascual
OBJECTIVE: To describe the pharmacological management of borderline personality disorder (BPD) in Spain from 2001 through 2016, the factors associated with prescriptions, and changes in pharmacotherapy over this time period. METHODS: Retrospective, cross-sectional, observational study conducted in a sample of 457 patients with BPD consecutively admitted to a specialist BPD Program between January 2001 and November 2016. Data on sociodemographic and clinical variables, as well as pharmacological treatment upon the admission to the programme, were used to describe pharmacological prescriptions, the factors associated with these medications, and changes in prescription over the last 15 years...
July 2, 2017: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/28668671/deutetrabenazine-for-treatment-of-involuntary-movements-in-patients-with-tardive-dyskinesia-aim-td-a-double-blind-randomised-placebo-controlled-phase-3-trial
#20
Karen E Anderson, David Stamler, Mat D Davis, Stewart A Factor, Robert A Hauser, Jouko Isojärvi, L Fredrik Jarskog, Joohi Jimenez-Shahed, Rajeev Kumar, Joseph P McEvoy, Stanislaw Ochudlo, William G Ondo, Hubert H Fernandez
BACKGROUND: Tardive dyskinesia results from exposure to dopamine receptor antagonists, such as typical and atypical antipsychotics. If clinically appropriate, clinicians often manage this disorder by lowering the dose of, or discontinuing, the causative drug. There is a significant unmet need for a treatment option that does not disrupt treatment regimens for underlying psychiatric illnesses. We aimed to assess the efficacy, safety, and tolerability of fixed doses of deutetrabenazine-a novel vesicular monoamine transporter-2 inhibitor-in patients with tardive dyskinesia...
June 28, 2017: Lancet Psychiatry
keyword
keyword
51699
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"